WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 314210
CAS#: 850649-62-6 (benzoate)
Description: Alogliptin benzoate is a DPP-4 inhibitor used for the treatment of Type 2 diabetes. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.
MedKoo Cat#: 314210
Name: Alogliptin benzoate
CAS#: 850649-62-6 (benzoate)
Chemical Formula: C25H27N5O4
Exact Mass:
Molecular Weight: 461.522
Elemental Analysis: C, 65.06; H, 5.90; N, 15.17; O, 13.87
Alogliptin benzoate, purity > 98%, is in stock. The same day shipping out after order is received.
Related CAS #: 850649-61-5 (free base)
Synonym: SYR322, SYR 322, SYR-322, Nesina, Kazano, Oseni, Alogliptin benzoate.
IUPAC/Chemical Name: (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile benzoate
InChi Key: KEJICOXJTRHYAK-XFULWGLBSA-N
InChi Code: InChI=1S/C18H21N5O2.C7H6O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19;8-7(9)6-4-2-1-3-5-6/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3;1-5H,(H,8,9)/t15-;/m1./s1
SMILES Code: O=C(O)C1=CC=CC=C1.N#CC2=CC=CC=C2CN(C(N3C)=O)C(N4C[C@H](N)CCC4)=CC3=O
The following data is based on the product molecular weight 461.522 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. Drug Des Devel Ther. 2013 Sep 17;7:989-1001. doi: 10.2147/DDDT.S37647. eCollection 2013. Review. PubMed PMID: 24068868; PubMed Central PMCID: PMC3782406.
2: Agrawal R, Bahare RS, Jain P, Dikshit SN, Ganguly S. Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin. Mini Rev Med Chem. 2012 Nov;12(13):1345-58. Review. PubMed PMID: 22512582.
3: Rendell M, Drincic A, Andukuri R. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012 Mar;13(4):553-63. doi: 10.1517/14656566.2012.656088. Epub 2012 Feb 1. Review. PubMed PMID: 22296609.
4: Ueki K. [A compounding agent of alogliptin and pioglitazone]. Nihon Rinsho. 2011 May;69(5):877-82. Review. Japanese. PubMed PMID: 21595275.
5: Tanabe A, Kaku K. [Alogliptin]. Nihon Rinsho. 2011 May;69(5):871-6. Review. Japanese. PubMed PMID: 21595274.
6: White JR. Alogliptin for the treatment of type 2 diabetes. Drugs Today (Barc). 2011 Feb;47(2):99-107. doi: 10.1358/dot.2011.47.2.1583163. Review. PubMed PMID: 21431099.
7: Takeuchi K, Fujita T, Hiroi S. [Pharmacological and clinical profile of alogliptin benzoate (NESINA®)]. Nihon Yakurigaku Zasshi. 2011 Jan;137(1):43-50. Review. Japanese. PubMed PMID: 21233588.
8: Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010 Oct 22;70(15):2051-72. doi: 10.2165/11205080-000000000-00000. Review. Erratum in: Drugs. 2010 Dec 24;70(18):2475. PubMed PMID: 20883057.
Related:
850649-62-6 (Alogliptin benzoate)
850649-61-5 (Alogliptin free base).
